GSK, Vir cleared to leap into PhIII, angling for a spot in the Covid-19 antibody race led by Lilly, Regeneron

Six months after GlaxoSmithKline paid $250 million for a stake in Vir Biotechnology and a seat at the table developing antibodies against Covid-19, it has a Phase III drug in its hands.

The partners said the independent data monitoring committee has given the green light to start the final stage of clinical testing after reviewing unblinded safety results, expanding the COMET-ICE study to more sites in North America, South America and Europe.